- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jan Berger Says Genetic Testing "Takes a Village"
Genetic and companion testing takes a village, according to Jan Berger, MD, MJ, president and chief executive officer of Health Intelligence Partners and editor-in-chief of The American Journal of Pharmacy Benefits.
Genetic and companion testing takes a village, according to Jan Berger, MD, MJ, president and chief executive officer of Health Intelligence Partners and editor-in-chief of The American Journal of Pharmacy Benefits.
Not only do the providers need to be in line, but so do the genetic counselors — if they’re available — and the industry is struggling with that as well as knowing the right processes to go through, she explained.
“So I think we need to come to a consensus on the right timing and the right process to put this all together to get the outcomes we’re looking for,” Dr Berger said.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
